Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Effectiveness of chemotherapy in newly detected patients with pulmonary tuberculosis with poly-resistance Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
The results of re-treatment patients with tuberculosis Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008
The evaluation of the relapse or treatment interrupted pulmonary tuberculosis cases Source: Eur Respir J 2006; 28: Suppl. 50, 21s Year: 2006
The characteristics of previous tuberculosis treatment programmes in patients with tuberculosis relapses Source: Eur Respir J 2001; 18: Suppl. 33, 473s Year: 2001
Directly observed therapy versus self administered therapy for patients of new smear positive pulmonary tuberculosis during hospitalisation period Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
The clinical value of intravenous pulse therapy in first retreatment pulmonary tuberculosis patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Tolerance to chemotherapy regimens with bedaquiline in adolescents with MDR/XDR pulmonary TB Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
The effect of antituberculosis chemotherapy on thyroid hormones in active pulmonary tuberculosis patients Source: Eur Respir J 2001; 18: Suppl. 33, 306s Year: 2001
The pharmacotherapy options for the intensive treatment phase in patients with primarily diagnosed pulmonary tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012
Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005